The expansion project will establish end-to-end capabilities including drug substance manufacturing, fill/finish, assembly, labelling and packaging in one site`
Japan-based Fujifilm Corporation has unveiled its plans to invest approximately $928m in the FUJIFILM Diosynth Biotechnologies’ site in Denmark.
FUJIFILM Diosynth is a Denmark-based contract development and manufacturing organisation (CDMO) that produces biologics and advanced therapies.
The new investment is aimed at expanding the current drug substance manufacturing capacity of the site, along with its capabilities to include fill/finish, and enhance its assembly, labelling and packaging services.
Fujifilm Corporation executive vice president and bio-CDMO division general manager Takatoshi Ishikawa said: “Our culture of innovation and reputation of manufacturing excellence ensures our rapid growth to better serve the healthcare community.
“Since the acquisition of the Denmark site last year, the facility’s strong manufacturing track-record, coupled with FUJIFILM Diosynth Biotechnologies’ technologies enabling a stable supply of high-quality biopharmaceuticals, has led to new orders not only from existing clients, but also new clients, contributing to our rapid business expansion.”
The investment will expand production and add fill/finish and packaging lines at Denmark site
The investment in Denmark-based biotechnology firm would expand the production lines for bulk drug substance, and add six new mammalian cell bioreactors by 2023. The expansion would also make the facility a large-scale bio-CDMO manufacturing facility in Denmark.
The development works include the addition of first fill/finish production line at the site by summer 2023, and installing a fully-automated, advanced system for producing up to 35 million units per annum.
In addition, a new packaging line will be equipped in spring 2022 to facilitate assembly of various auto-injector types along with automatic labelling to meet wide-ranging customer needs.
Fujifilm has invested approximately $890m in August 2019 to acquire Biogen’s manufacturing subsidiary in Denmark, for its advanced cGMP capabilities and its experienced talent.
FUJIFILM Diosynth Biotechnologies chief executive officer Martin Meeson said: “With the addition of world-class assets enabling us to scale production volumes to fit both small and large batches, the capital infusion allows us to deliver on our promise to support our partners from pre-clinical through to commercialisation.
“Moreover, we are able to support our partners in manufacturing lifesaving therapies to patients around the world.”